Improving In Vivo Models for Preclinical Drug Development
Effective preclinical drug development hinges on the selection of robust in vivo models that accurately recapitulate glp-certified pre-clinical cro human disease and response to therapy. Optimizing these models involves a multifaceted approach, encompassing careful evaluation of species determination, genetic background, disease presentation, and e